Musculoskeletal Pain Pipeline Insight, 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Musculoskeletal Pain Pipeline
"Musculoskeletal Pain Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Musculoskeletal Pain market. A detailed picture of the Musculoskeletal Pain pipeline landscape is provided, which includes the disease overview and Musculoskeletal Pain treatment guidelines. The assessment part of the report embraces in-depth Musculoskeletal Pain commercial assessment and clinical assessment of the Musculoskeletal Pain pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Musculoskeletal Pain collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Musculoskeletal pain affects the bones, muscles, ligaments, tendons, and nerves, with the pain ranging from mild to severe enough to interfere with day-to-day life. It may start suddenly and be short-lived, which is called acute pain. Pain that lasts for more time is called chronic pain. Musculoskeletal pain can be localized in one area, or widespread. The most common cause of musculoskeletal pain is an injury to the bones, joints, muscles, tendons, or ligaments. Falls, sports injuries, and car accidents are just a few of the incidents that can lead to pain. People with musculoskeletal pain sometimes complain that their entire bodies ache. Their muscles may feel like they have been pulled or overworked. Sometimes, the muscles twitch or burn. Symptoms vary from person to person, but the common symptoms are Pain, Fatigue, Sleep disturbances.
View free sample page: - https://www.delveinsight.com/sample-request/musculoskeletal-pain-pipeline-insight
Musculoskeletal Pain Pipeline
DelveInsight has performed detailed historical market analysis for Musculoskeletal Pain. In the coming years, the competitive landscape for the Musculoskeletal Pain market is set to change due to rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The launch of emerging therapies such, Tanezumab (Eli Lilly/Pfizer), Fasinumab (Regeneron Pharmaceuticals), MPC-06-ID (Mesoblast), CAM2038 (Braeburn Pharmaceuticals), and others will significantly impact the Musculoskeletal Pain market during the study period (2017-2030). While some of the companies have recently shifted their focus towards this indication, yet others are expected to create a significant influence on the market size during the forecast period. Tanezumab (Eli Lilly/Pfizer) is an investigational monoclonal antibody that works by selectively targeting, binding to, and inhibiting NGF. NGF levels increase in the body as a result of injury, inflammation, or chronic pain states. By inhibiting NGF, it may help to keep pain signals produced by muscles, skin, and organs from reaching the spinal cord and brain. Recently US FDA accepts regulatory submission For Tanezumab, a potential first-in-class treatment for patients with chronic pain due to moderate-to-severe osteoarthritis. The US FDA has also granted Fast Track designation for Tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Emerging therapies included in the report
• Tanezumab: Eli Lilly/Pfizer
• Fasinumab: Regeneron Pharmaceuticals
• CAM2038: Braeburn Pharmaceuticals
Musculoskeletal Pain Report Scope
• The Musculoskeletal Pain report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Musculoskeletal Pain across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Musculoskeletal Pain therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Musculoskeletal Pain research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Musculoskeletal Pain.
Download free sample page:- https://www.delveinsight.com/sample-request/musculoskeletal-pain-pipeline-insight
Table of content
1. Report Introduction
2. Musculoskeletal Pain
3. Musculoskeletal Pain Current Treatment Patterns
4. Musculoskeletal Pain - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Musculoskeletal Pain Late Stage Products (Phase-III)
7. Musculoskeletal Pain Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Musculoskeletal Pain Discontinued Products
13. Musculoskeletal Pain Product Profiles
14. Musculoskeletal Pain Key Companies
15. Musculoskeletal Pain Key Products
16. Dormant and Discontinued Products
17. Musculoskeletal Pain Unmet Needs
18. Musculoskeletal Pain Future Perspectives
19. Musculoskeletal Pain Analyst Review
20. Appendix
21. Report Methodology

A20, near to Maxfort School, Sector 7 Dwarka, Dwarka, New Delhi, Delhi 110077, India

Related Reports
• Musculoskeletal Pain- Market Insight, Epidemiology and Market Forecast -2030
• Musculoskeletal Pain - Epidemiology Forecast to 2030

This release was published on openPR.